Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists
Adverse events  · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 17 participantsVery low
Findings
What do systematic reviews say?
2 questions · 2 findings · 1 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Short‐acting inhaled beta‐2 agonists vs placebo
Adverse events  · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events  compared with placebo (very low certainty).
1 finding from 1 review
- no estimate extracted3 studies · 47 participantsVery low